Overview
• To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece
Description
- To capture the treatment patterns and clinical characteristics of patients with ER/PR
positive, HER2-negative MBC in Greece
- To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival
- To record adverse events per line of therapy
- To recording of the causes of treatment discontinuation per line of therapy
Eligibility
Inclusion Criteria:
- Women with histological confirmed ER/PR positive, HER2-negative MBC
- Age >18 years old
- Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC
- Adequate hematologic, renal and hepatic function
- Signed informed consent (ICF)
Exclusion Criteria:
- Active malignancy other than MBC
- Active infection